Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Profits Appear To Have Quality Issues

The recent earnings posted by Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHSE:600513) were solid, but the stock didn't move as much as we expected. However the statutory profit number doesn't tell the whole story, and we have found some factors which might be of concern to shareholders.

Check out our latest analysis for Jiangsu Lianhuan Pharmaceutical

How Do Unusual Items Influence Profit?

Importantly, our data indicates that Jiangsu Lianhuan Pharmaceutical's profit received a boost of CN¥20m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jiangsu Lianhuan Pharmaceutical.

Our Take On Jiangsu Lianhuan Pharmaceutical's Profit Performance

Arguably, Jiangsu Lianhuan Pharmaceutical's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Jiangsu Lianhuan Pharmaceutical's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 23% per annum growth in EPS for the last three. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. To help with this, we've discovered 2 warning signs (1 is a bit unpleasant!) that you ought to be aware of before buying any shares in Jiangsu Lianhuan Pharmaceutical.

Today we've zoomed in on a single data point to better understand the nature of Jiangsu Lianhuan Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.